Pamol 1000 mg tabletti Finlandiya - Fince - Fimea (Suomen lääkevirasto)

pamol 1000 mg tabletti

orifarm healthcare a/s - paracetamol - tabletti - 1000 mg - parasetamoli

Tagrisso Avrupa Birliği - Fince - EMA (European Medicines Agency)

tagrisso

astrazeneca ab - osimertinib mesilate - karsinooma, ei-pienisoluinen keuhko - muut antineoplastiset aineet, proteiinikinaasin estäjät - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Hydrocortison 1 % emulsiovoide Finlandiya - Fince - Fimea (Suomen lääkevirasto)

hydrocortison 1 % emulsiovoide

orion corporation - hydrocortisone - emulsiovoide - 1 % - hydrokortisoni

Hydrocortison 2.5 % emulsiovoide Finlandiya - Fince - Fimea (Suomen lääkevirasto)

hydrocortison 2.5 % emulsiovoide

orion corporation - hydrocortisone - emulsiovoide - 2.5 % - hydrokortisoni

Pantyson 10 mg/g + 20 mg/g emulsiovoide Finlandiya - Fince - Fimea (Suomen lääkevirasto)

pantyson 10 mg/g + 20 mg/g emulsiovoide

orion corporation - dexpanthenol, hydrocortisone - emulsiovoide - 10 mg/g + 20 mg/g - hydrokortisoni

Sibicort 10 mg/g + 10 mg/g emulsiovoide Finlandiya - Fince - Fimea (Suomen lääkevirasto)

sibicort 10 mg/g + 10 mg/g emulsiovoide

orion corporation - chlorhexidine digluconate, hydrocortisone - emulsiovoide - 10 mg/g + 10 mg/g - hydrokortisoni ja antiseptit

Hydrocortison 10 mg/ml liuos iholle Finlandiya - Fince - Fimea (Suomen lääkevirasto)

hydrocortison 10 mg/ml liuos iholle

orion corporation - hydrocortisone - liuos iholle - 10 mg/ml - hydrokortisoni

Hydrocortison 0.5 % emulsiovoide Finlandiya - Fince - Fimea (Suomen lääkevirasto)

hydrocortison 0.5 % emulsiovoide

orion corporation - hydrocortisone - emulsiovoide - 0.5 % - hydrokortisoni

Zoviduo 50 mg/g + 10 mg/g emulsiovoide Finlandiya - Fince - Fimea (Suomen lääkevirasto)

zoviduo 50 mg/g + 10 mg/g emulsiovoide

haleon denmark aps - aciclovir, hydrocortisone - emulsiovoide - 50 mg/g + 10 mg/g - asikloviiri

Verzenios Avrupa Birliği - Fince - EMA (European Medicines Agency)

verzenios

eli lilly nederland b.v. - abemaciclib - rintojen kasvaimet - antineoplastiset aineet - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.